MultiScreen™ β-Arrestin Sensor
high throughput detection of biased signaling
of GPCRs in MultiScreen™ or primary cells
MultiScreen™ β-Arrestin technology
The properties of a ligand that preferentially activate or inhibit one pathway over another are described as signaling bias and screening compounds for biased signaling may lead to selective perturbation of disease-specific pathways. Measuring compound activities in assays in the same cellular environment using unmodified GPCRs, recombinant or native, is key for accurate signaling bias analysis. Our newly developed proprietary MultiScreen™ β-Arrestin technology overcomes the receptor-tagging drawback of other existing technologies, enabling high-throughput detection of β-Arrestin translocation induced by native GPCRs in vitro and in vivo for the first time.